Achieve Life Sciences (NASDAQ:ACHV) Hits New 12-Month High – Here’s Why

Achieve Life Sciences, Inc. (NASDAQ:ACHV)’s stock price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $7.15 and last traded at $6.9820, with a volume of 283812 shares traded. The stock had previously closed at $6.69.

More Achieve Life Sciences News

Here are the key news stories impacting Achieve Life Sciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $12 price target, well above the stock’s recent opening price near $7.03. The firm modestly improved its Q3 2026, Q4 2026 and FY2027 EPS forecasts, with expected losses narrowing to $(0.22), $(0.26) and $(0.79), respectively.
• Positive Sentiment: Shares have risen sharply over the past year—nearly tripling—reflecting investor expectations that Achieve’s smoking-cessation drug candidate can eventually support a profitable commercial business. Achieve Life Sciences stock has nearly tripled in the last year
• Positive Sentiment: HC Wainwright’s estimates still project a transition to positive earnings beginning in FY2028, reaching $0.23 per share in FY2028, $0.97 in FY2029 and $1.47 in FY2030, despite modest reductions to those forecasts.
• Neutral Sentiment: Achieve Life Sciences reported second-quarter 2026 financial results and provided business updates. The results are an important catalyst for investors evaluating clinical progress, regulatory timing and the company’s path toward commercialization. Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Updates
• Negative Sentiment: HC Wainwright sharply lowered its FY2026 EPS forecast to a loss of $(1.54), from $(0.92), substantially below the consensus estimate of $(0.81). The company also recently reported quarterly EPS of $(0.80), missing the $(0.16) consensus estimate.
• Negative Sentiment: Longer-term earnings estimates were trimmed slightly: FY2028 fell to $0.23 from $0.24, FY2029 to $0.97 from $1.00, and FY2030 to $1.47 from $1.51. These revisions reinforce that profitability remains dependent on successful development and commercialization.

Analyst Ratings Changes

Several brokerages have recently weighed in on ACHV. Canaccord Genuity Group set a $13.00 price objective on shares of Achieve Life Sciences and gave the stock a “buy” rating in a report on Monday, April 20th. Weiss Ratings raised shares of Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Raymond James Financial restated a “strong-buy” rating and issued a $18.00 target price on shares of Achieve Life Sciences in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a research report on Wednesday. Finally, UBS Group reaffirmed a “buy” rating on shares of Achieve Life Sciences in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $15.00.

Achieve Life Sciences Stock Up 5.2%

The firm has a 50-day simple moving average of $6.03 and a 200 day simple moving average of $4.90. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.62 and a quick ratio of 2.62. The company has a market capitalization of $722.62 million, a PE ratio of -4.54 and a beta of 2.24.

Achieve Life Sciences (NASDAQ:ACHV) last issued its earnings results on Tuesday, August 11th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.64). On average, research analysts predict that Achieve Life Sciences, Inc. will post -0.81 EPS for the current fiscal year.

Hedge Funds Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Keating Financial Advisory Services Inc. acquired a new stake in Achieve Life Sciences in the second quarter valued at approximately $163,000. BlackRock Inc. acquired a new position in shares of Achieve Life Sciences during the second quarter worth $34,426,000. Deutsche Bank AG acquired a new position in shares of Achieve Life Sciences during the second quarter worth $506,000. Bank of New York Mellon Corp purchased a new position in shares of Achieve Life Sciences in the second quarter valued at $1,424,000. Finally, Next Capital Management LLC purchased a new position in shares of Achieve Life Sciences in the second quarter valued at $229,000. Hedge funds and other institutional investors own 33.52% of the company’s stock.

About Achieve Life Sciences

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.